Genentech and Biogen Idec received FDA approval of Rituxan in combination with fludarabine and cyclophosphamide (FC) for people with previously treated/untreated CD20-positive chronic lymphocytic leukemia (CLL). CLL is the most common form of adult leukemia and is a slow-growing cancer that occurs when abnormal or malignant white blood cells are found in the blood and bone marrow. Since the disease is considered incurable, the treatment aims to increase progression-free survival. “Rituxan ...